Finance

Lists
ICY:FRA
Incyte Corp
€108.10
-0.23%
(-0.25) 1D
Nov 18, 10:00:00 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ICY...
Open
€108.10
High
€108.10
Low
€108.10
Mkt. cap
24.01B
Avg. vol.
66.00
Volume
0.00
52-wk high
€115.40
52-wk low
€77.60
No. of employees
3K
Open
€108.10
High
€108.10
Low
€108.10
Mkt. cap
24.01B
Avg. vol.
66.00
Volume
0.00
52-wk high
€115.40
52-wk low
€77.60
No. of employees
3K
News stories
From web sources and news partners
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEO-
Employees2.84K
Founded2002
HeadquartersWilmington, Delaware, United States
SectorHealth Care
IndustryBiotechnology
Websiteincyte.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.51B
1.27B
1.67B
1.56B
Cost of goods sold
732.55M
620.43M
621.91M
668.90M
Cost of revenue
732.55M
620.43M
621.91M
668.90M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
388.96M
327.06M
350.72M
363.29M
Operating expense
388.96M
327.06M
350.72M
363.29M
Total operating expenses
1.12B
947.49M
972.63M
1.03B
Operating income
385.32M
325.19M
701.41M
525.01M
Other non operating income
4.22M
1.75M
5.26M
186.00K
EBT including unusual items
389.94M
343.60M
751.51M
-688.85M
EBT excluding unusual items
419.71M
360.06M
744.21M
556.77M
Income tax expense
90.66M
40.27M
165.91M
95.96M
Effective tax rate
23.25%
11.72%
22.08%
-13.93%
Other operating expenses
-
-
-
-
Net income
299.28M
303.33M
585.60M
-784.80M
Net profit margin
19.86%
23.83%
34.98%
-50.40%
Earnings per share
1.80
1.81
3.09
-3.60
Interest and investment income
30.75M
33.69M
38.12M
32.17M
Interest expense
-582.00K
-569.00K
-582.00K
-605.00K
Net interest expenses
30.17M
33.12M
37.54M
31.57M
Depreciation and amortization charges
-
-
-
-
EBITDA
409.30M
348.99M
727.89M
549.19M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps